Rob Coker Deputy Editor of The Medicine Maker

Scientists develop treatment that leads to complete regression of breast tumors in mice.

How snake venom, genomic data, and deep learning computation methods have combined to bring new advances in drug discovery.

US-based pharmaceutical associations fear the supply chain repercussions of tariffs, and offer advice for a more sustainable alternative.

With US courts consistently ruling in favor of the PrEP drug manufacture, the CDC and DHHS have had no choice but to be humble.

Summarizing the updated lessons learned by the European Medicines Agency following the COVID-19 pandemic.

A look back at The Medicine Maker archive and the influence of science fiction in the industry and science.

So you know your small molecule from your AAV, but can you unscramble the names of these 2024 novel drug approvals?

EU-based associations voice concerns over joint clinical assessments and the lack of advice meetings.

A rundown of the latest developments and approvals in the world of small molecules drugs manufacturing.

A Pistoia Alliance survey looks at stakeholder concerns in AI regulations, and calls for more harmonization and collaboration.